Eindelijk wat RCH nieuws:
https://replicel.com/news/japan-s-re...erapy-products
“This provides a clear signal to Japanese investors, clinicians, and strategic partners with whom we are in discussions, that we are delivering on our ‘First-in-Japan’ strategy which aims to have four products on the market in Japan by 2023.” -
Replicel
https://replicel.com/news/publicatio...-men-and-women
"
We are very pleased that the data from this randomized, placebo-controlled, double-blinded, dose-ranging clinical study of 65 patients (male and female) with pattern hair loss confirms, with statistical significance, the observations from our ph 1 trial in a larger cohort of patients including females, a wide variety of ages and hair loss, and compared with a placebo-control. In summary, the study produced a statistically significant and clinically meaningful increase in hair density and diameter as measured nine months after treatment,” stated RepliCel’s Chief Medical Officer, Dr. Rolf Hoffman.
Dus kan commercieel verkrijgbaar worden in 2023 in Japan. Ik verwacht ook nog efficacy studies dat Shiseido zal uitvoeren in de nabije toekomst.